General Information of This Drug (ID: DM5GIWZ)

Drug Name
Mirogabalin   DM5GIWZ
Synonyms
Mirogabalin; 1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Registered Indication(s)
Indication Name Indication ID ICD-11 Status REF
Peripheral neuropathy DIS7KN5G 8C0Z Registered [1]
------------------------------------------------------------------------------------
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cardiovascular disease DIS2IQDX BA00-BE2Z Phase 3 [2]
Fibromyalgia DISZJDS2 MG30.01 Phase 3 [3]
------------------------------------------------------------------------------------

References

1 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8303).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)